Literature DB >> 6859081

Complications of therapeutic apheresis, including a fatal case with pulmonary vascular occlusion.

M D Rubenstein, R T Wall, G S Wood, M A Edwards.   

Abstract

A high incidence of anaphylactic reactions has been observed in patients undergoing therapeutic plasma exchange. In three of 22 patients who underwent multiple exchanges, urticaria, bronchospasm, and hypotension developed during a course of plasma exchange that responded to treatment with steroids, antihistamines, and epinephrine. Fatal pulmonary microvascular occlusion with platelets and granulocytes developed in an additional patient eight hours following an apheresis procedure involving albumin replacement. The mechanism for the latter complication is not known but did not appear to invoke complement activation. This unexpectedly high risk of potentially fatal complications must be considered when a course of therapeutic apheresis, particularly involving treatment of a chronic disease, is planned.

Entities:  

Mesh:

Year:  1983        PMID: 6859081     DOI: 10.1016/0002-9343(83)91184-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Activation of complement during apheresis.

Authors:  G Hetland; T E Mollnes; P Garred
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

Review 2.  Plasmapheresis: technique and complications.

Authors:  P M Reimann; P D Mason
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

3.  Role of plasmapheresis in primary biliary cirrhosis.

Authors:  L B Cohen; E P Ambinder; A M Wolke; S P Field; F Schaffner
Journal:  Gut       Date:  1985-03       Impact factor: 23.059

4.  A porcine model of hemodialyzer reactions: roles of complement activation and rinsing back of extracorporeal blood.

Authors:  Ákos Pethő; Dorothea Piecha; Tamás Mészáros; Rudolf Urbanics; Christoph Moore; Bernard Canaud; László Rosivall; Tom Eirik Mollnes; Sonja Steppan; Gábor Szénási; János Szebeni; László Dézsi
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.